In May, SR419, a drug candidate with a novel mechanism of action for the treatment of peripheral neuropathic pain, was granted fast track designation (FTD) by the U.S. Food and Drug Administration (FD
发布时间：2022年11月18日
In May, SR419, a drug candidate with a novel mechanism of action for the treatment of peripheral neuropathic pain, was granted fast track designation (FTD) by the U.S. Food and Drug Administration (FDA).
